Treatment of pharmacoresistant epilepsy

A method for treating epilepsy, the method comprising administering to a subject in need thereof a compound of formula (I):

• or a pharmaceutically acceptable salt of the compound of formula (I) in the form of a hydrate, solvate, or complex, where in formula (I):
• X is selected from C═O, CH—OH, CH2 and C═N—, with the proviso that if X is C═N—, the nitrogen is bound to a nitrogen atom of an R1 substituent;
• R1 is selected from the group consisting of:
• hydrogen, methyl, or a linear or branched C2-C4 alkyl;
• an aromatic or aliphatic 5 membered ring, optionally comprising heteroatoms and/or optionally comprising further substituents;
• an aromatic or aliphatic 6 membered ring, optionally comprising one or more heteroatoms and/or optionally comprising further substituents;
• and
• a double 6 membered ring, wherein one or both rings are aromatic and optionally comprising one or more hetero atoms, and/or optionally comprising further substituents;
• and
• R2 is selected from the group consisting of:
• phenyl, optionally substituted with OH, OCH3, ethyl, halomethyl, one or more halogens, or with a linear or branched C2-C8 alkyl, where the C2-C8 alkyl is optionally further substituted with ═O or where a carbon atom in the C2-C8 alkyl is replaced with a halogen;
• and
• a linear or branched C1-C10 alkyl in which a carbon atom is optionally replaced with a Si atom;
• and
• a C3-C6 cycloalkyl.

A compound having formula (I):

• where:
• X is selected from C═O, CH—OH, —CH2 or C═N—, with the proviso that if X is C═N—, the nitrogen of the C═N— is bound to a nitrogen atom of an R1 substituent;
• R1 is selected from the group consisting of:
• hydrogen, methyl or a linear or branched C2-C4 alkyl;
• an aromatic or aliphatic 5 membered ring, optionally comprising heteroatoms and/or optionally comprising further substituents;
• an aromatic or aliphatic 6 membered ring, optionally comprising one or more heteroatoms and/or optionally comprising further substituents;
• and
• a double 6 membered ring, wherein one or both rings are aromatic and optionally comprising one or more hetero atoms, and/or optionally comprising further substituents, and
• R2 is selected from the group consisting of:
• phenyl, optionally further substituted with —OH, —OCH3, ethyl, halomethyl, one or more halogens, or with a linear or branched C2-C8 alkyl, wherein the C2-C8 alkyl is optionally further substituted with ═O or wherein a carbon atom in the C2-C8 alkyl is replaced with a halogen;
• a linear or branched C1-C10 alkyl, in which a carbon atom is optionally replaced with a Si atom;
• and
• a C3-C6 cycloalkyl.